Crimson Publishers Publish With Us Reprints e-Books Video articles


Surgical Medicine Open Access Journal

Investigation of the Efficacy of Aged Algan Hemostatic Agent in Experimental Femoral Artery Bleeding Model in Rats

Submission:November 5, 2021;Published: February 28, 2022

DOI: 10.31031/SMOAJ.2022.04.000596

ISSN : 2578-0379
Volume4 Issue5


Effective and fast-acting hemorrhage stopper materials are still needed in the first intervention of trauma patients with large vessel injuries. In this study, we investigated the efficacy of aged Algan Hemostatic Agent® (AHA) in an experimental rat model with femoral artery hemorrhage. In this study, 21 male rats, 5-7 weeks old and weighing 200-250 grams, were used. Rats were randomly divided into three groups, 7 animals in each group. The femoral artery and vein were visualized and bleeding was initiated with an incision. Bleeding time was recorded. Those whose bleeding stopped in the first two minutes were evaluated as those whose bleeding stopped in the first four minutes. If bleeding still continued after the fourth minute, it was recorded as unsuccessful. In the study group, bleeding could be controlled in 5 rats in the first application and in two rats in the second application. In the control group animals, hemorrhagic shock findings were detected because the bleeding could not be controlled after femoral artery bleeding. The difference between the AHA and control groups was statistically significant (p=0.001). It is known that the main treatment for the control of large arterial hemorrhages is surgical hemorrhage control. However, products with practical applicability can be used in non-hospital areas. According to our research results, it was determined that the 4-year-old AHA product successfully maintained its astringent activity. According to the results of the study, it was concluded that the AHA hemostatic product can be used as a first-aid hemorrhage stopper in practice.

Keywords:Algan hemostatic agent; Bleeding; Femoral artery; Hemostazis; Rat

Abbreviations:AHA: Algan Hemostatic Agent®; TRAP: Thrombin-Receptor-Agonist-Peptide

Get access to the full text of this article